Overview

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
OBJECTIVES: I. Evaluate the efficacy of related, HLA-identical bone marrow transplantation following cyclophosphamide (CTX) and antithymocyte globulin in patients with aplastic anemia. II. Evaluate the efficacy of related, HLA-nonidentical bone marrow transplantation following CTX and total-body irradiation/total-lymphoid irradiation in patients with aplastic anemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborator:
University of California, Los Angeles
Treatments:
Antilymphocyte Serum
Cyclophosphamide
Cyclosporine
Cyclosporins
Methotrexate
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Severe aplastic anemia with 2 of the following criteria:
Polymorphonuclear neutrophils no more than 0.5 x 10 to the ninth/L Platelets no more than
20 x 10 to the ninth/L Reticulocytes no more than 30 x 10 to the ninth/L Hypocellular bone
marrow Related donor aged 6 weeks or more, matching at least 4 of 6 HLA A, B, and DRI loci,
as follows: HLA-identical family member for patients aged less than 40 years
HLA-nonidentical family member for patients aged less than 55 years failing antithymocyte
globulin or other immunosuppressive therapy The following eligible for transplantation as
initial therapy: Patients aged less than 40 years with HLA-matched donor Patients aged
40-45 years with HLA-identical donor No neoplastic or preneoplastic evolution --Patient
Characteristics-- Age: Under 40 (55 if ATG failure) Hepatic: No severe liver dysfunction
Renal: No severe renal dysfunction Cardiovascular: No severe cardiac dysfunction Other: No
other organ dysfunction that would compromise survival after transplant No HIV infection